Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease
Identifieur interne : 005C49 ( Main/Merge ); précédent : 005C48; suivant : 005C50Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease
Auteurs : Paul S. Fitzmaurice [Canada] ; Lee Ang [Canada] ; Mark Guttman [Canada] ; Ali H. Rajput [Canada] ; Yoshiaki Furukawa [Canada] ; Stephen J. Kish [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-09.
English descriptors
- KwdEn :
- Aged, Antioxidants (metabolism), Glutathione (deficiency), Humans, Multiple System Atrophy (metabolism), Oxidative Stress, Parkinson Disease (metabolism), Parkinson's disease, Substantia Nigra (metabolism), Supranuclear Palsy, Progressive (metabolism), Uric Acid (metabolism), glutathione, multiple system atrophy, oxidative stress, progressive supranuclear palsy, substantia nigra.
- MESH :
- chemical , deficiency : Glutathione.
- chemical , metabolism : Antioxidants, Uric Acid.
- metabolism : Multiple System Atrophy, Parkinson Disease, Substantia Nigra, Supranuclear Palsy, Progressive.
- Aged, Humans, Oxidative Stress.
Abstract
The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [−30%], PSP [−21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance (P = 0.078, MSA [−20%]). GSH levels were normal in all examined normal and degenerating extra‐nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (−19 to −30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10486
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000413
- to stream Istex, to step Curation: 000413
- to stream Istex, to step Checkpoint: 002956
- to stream PubMed, to step Corpus: 003705
- to stream PubMed, to step Curation: 003705
- to stream PubMed, to step Checkpoint: 003718
- to stream Ncbi, to step Merge: 000B59
- to stream Ncbi, to step Curation: 000B59
- to stream Ncbi, to step Checkpoint: 000B59
Links to Exploration step
ISTEX:57555A8D09E20110590BCE420F0B37968371034DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:57555A8D09E20110590BCE420F0B37968371034D</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10486</idno>
<idno type="url">https://api.istex.fr/document/57555A8D09E20110590BCE420F0B37968371034D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000413</idno>
<idno type="wicri:Area/Istex/Curation">000413</idno>
<idno type="wicri:Area/Istex/Checkpoint">002956</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14502663</idno>
<idno type="wicri:Area/PubMed/Corpus">003705</idno>
<idno type="wicri:Area/PubMed/Curation">003705</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003718</idno>
<idno type="wicri:Area/Ncbi/Merge">000B59</idno>
<idno type="wicri:Area/Ncbi/Curation">000B59</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B59</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
<idno type="wicri:Area/Main/Merge">005C49</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neuropathology, London Health Science Centre, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-09">2003-09</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="969">969</biblScope>
<biblScope unit="page" to="976">976</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">57555A8D09E20110590BCE420F0B37968371034D</idno>
<idno type="DOI">10.1002/mds.10486</idno>
<idno type="ArticleID">MDS10486</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antioxidants (metabolism)</term>
<term>Glutathione (deficiency)</term>
<term>Humans</term>
<term>Multiple System Atrophy (metabolism)</term>
<term>Oxidative Stress</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson's disease</term>
<term>Substantia Nigra (metabolism)</term>
<term>Supranuclear Palsy, Progressive (metabolism)</term>
<term>Uric Acid (metabolism)</term>
<term>glutathione</term>
<term>multiple system atrophy</term>
<term>oxidative stress</term>
<term>progressive supranuclear palsy</term>
<term>substantia nigra</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Glutathione</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antioxidants</term>
<term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
<term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Humans</term>
<term>Oxidative Stress</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [−30%], PSP [−21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance (P = 0.078, MSA [−20%]). GSH levels were normal in all examined normal and degenerating extra‐nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (−19 to −30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.10486"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:57555A8D09E20110590BCE420F0B37968371034D</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10486</idno>
<idno type="url">https://api.istex.fr/document/57555A8D09E20110590BCE420F0B37968371034D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000413</idno>
<idno type="wicri:Area/Istex/Curation">000413</idno>
<idno type="wicri:Area/Istex/Checkpoint">002956</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S." last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neuropathology, London Health Science Centre, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea>
<wicri:noRegion>Saskatchewan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-09">2003-09</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="969">969</biblScope>
<biblScope unit="page" to="976">976</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">57555A8D09E20110590BCE420F0B37968371034D</idno>
<idno type="DOI">10.1002/mds.10486</idno>
<idno type="ArticleID">MDS10486</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>glutathione</term>
<term>multiple system atrophy</term>
<term>oxidative stress</term>
<term>progressive supranuclear palsy</term>
<term>substantia nigra</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [−30%], PSP [−21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance (P = 0.078, MSA [−20%]). GSH levels were normal in all examined normal and degenerating extra‐nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (−19 to −30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD. © 2003 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S" last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation wicri:level="1"><nlm:affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. Paul_fitzmaurice@camh.net</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H" last="Rajput">Ali H. Rajput</name>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14502663</idno>
<idno type="pmid">14502663</idno>
<idno type="doi">10.1002/mds.10486</idno>
<idno type="wicri:Area/PubMed/Corpus">003705</idno>
<idno type="wicri:Area/PubMed/Curation">003705</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003718</idno>
<idno type="wicri:Area/Ncbi/Merge">000B59</idno>
<idno type="wicri:Area/Ncbi/Curation">000B59</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B59</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Fitzmaurice P:nigral:glutathione:deficiency</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.</title>
<author><name sortKey="Fitzmaurice, Paul S" sort="Fitzmaurice, Paul S" uniqKey="Fitzmaurice P" first="Paul S" last="Fitzmaurice">Paul S. Fitzmaurice</name>
<affiliation wicri:level="1"><nlm:affiliation>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. Paul_fitzmaurice@camh.net</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ang, Lee" sort="Ang, Lee" uniqKey="Ang L" first="Lee" last="Ang">Lee Ang</name>
</author>
<author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H" last="Rajput">Ali H. Rajput</name>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antioxidants (metabolism)</term>
<term>Glutathione (deficiency)</term>
<term>Humans</term>
<term>Multiple System Atrophy (metabolism)</term>
<term>Oxidative Stress</term>
<term>Parkinson Disease (metabolism)</term>
<term>Substantia Nigra (metabolism)</term>
<term>Supranuclear Palsy, Progressive (metabolism)</term>
<term>Uric Acid (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Glutathione</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antioxidants</term>
<term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
<term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Humans</term>
<term>Oxidative Stress</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The consistent findings of decreased levels of the major antioxidant glutathione in substantia nigra of patients with idiopathic Parkinson's disease (PD) has provided most of the basis for the oxidative stress hypothesis of the etiology of PD. To establish whether a nigral glutathione deficiency is unique to PD, as is generally assumed, or is present in other Parkinsonian conditions associated with nigral damage, we compared levels of reduced glutathione (GSH) in postmortem brain of patients with PD to those with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). As compared with the controls, nigral GSH levels were decreased in the PD and PSP patient groups (P < 0.05 for PD [-30%], PSP [-21%]), whereas a similar decrease in the MSA patient group did not reach statistical significance (P = 0.078, MSA [-20%]). GSH levels were normal in all examined normal and degenerating extra-nigral brain areas in PSP and MSA. A trend for decreased levels of uric acid (antioxidant and product of purine catabolism) also was observed in nigra of all patient groups (-19 to -30%). These data suggest that glutathione depletion, possibly consequent to overutilisation in oxidative stress reactions, could play a causal role in nigral degeneration in all nigrostriatal dopamine deficiency disorders, and that antioxidant therapeutic approaches should not be restricted to PD.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005C49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005C49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:57555A8D09E20110590BCE420F0B37968371034D |texte= Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |